BACKGROUND: Although several studies have reported correlations between infections and coronary artery disease, associations with endothelial dysfunction, its precursor, have not been established. This study assessed whether infection with Chlamydia pneumoniae (CP), cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Helicobacter pylori (HP) is associated with decreased endothelial function. METHODS AND RESULTS: Sixty-five male subjects, aged 20 to 45 years, with no risk factors or known coronary artery disease were enrolled in a seroepidemiological cross-sectional study. Endothelial function was determined by flow-mediated brachial vasodilation. Serum antibodies consisting of anti-CP IgG and IgM, anti-CMV IgG, anti-EBV nuclear antigen, and anti-HP IgG and markers of inflammation including high-sensitivity C-reactive protein were measured. Average age was 29.3+/-5.5 years. Seroprevalence values were 65.1%, 34.9%, 88.9%, and 14.3% for CP, CMV, EBV, and HP, respectively. Average values for endothelium-dependent and -independent vasodilation were 9.4+/-4.5% and 12.6+/-5.0%. Despite adequate statistical power (82% for the primary end point), no association between endothelial function and seropositivity to individual infectious agents, infectious burden, or C-reactive protein was observed in regression analyses controlling for variables including age, blood pressure, and lipid parameters. Moreover, no dose-response trends between serum titers and endothelial function were found. CONCLUSIONS: Lack of association between chronic infection with CP, CMV, EBV, HP, or pathogen burden and endothelial function was observed, suggesting that these agents are not implicated as early etiologic triggers in the genesis of coronary artery disease. These results do not preclude active involvement at later stages of the pathophysiological process, such as acceleration of existing atherosclerosis and acute plaque rupture.
BACKGROUND: Although several studies have reported correlations between infections and coronary artery disease, associations with endothelial dysfunction, its precursor, have not been established. This study assessed whether infection with Chlamydia pneumoniae (CP), cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Helicobacter pylori (HP) is associated with decreased endothelial function. METHODS AND RESULTS: Sixty-five male subjects, aged 20 to 45 years, with no risk factors or known coronary artery disease were enrolled in a seroepidemiological cross-sectional study. Endothelial function was determined by flow-mediated brachial vasodilation. Serum antibodies consisting of anti-CP IgG and IgM, anti-CMV IgG, anti-EBV nuclear antigen, and anti-HP IgG and markers of inflammation including high-sensitivity C-reactive protein were measured. Average age was 29.3+/-5.5 years. Seroprevalence values were 65.1%, 34.9%, 88.9%, and 14.3% for CP, CMV, EBV, and HP, respectively. Average values for endothelium-dependent and -independent vasodilation were 9.4+/-4.5% and 12.6+/-5.0%. Despite adequate statistical power (82% for the primary end point), no association between endothelial function and seropositivity to individual infectious agents, infectious burden, or C-reactive protein was observed in regression analyses controlling for variables including age, blood pressure, and lipid parameters. Moreover, no dose-response trends between serum titers and endothelial function were found. CONCLUSIONS: Lack of association between chronic infection with CP, CMV, EBV, HP, or pathogen burden and endothelial function was observed, suggesting that these agents are not implicated as early etiologic triggers in the genesis of coronary artery disease. These results do not preclude active involvement at later stages of the pathophysiological process, such as acceleration of existing atherosclerosis and acute plaque rupture.
Authors: Anna Lebedeva; Elena Maryukhnich; Jean-Charles Grivel; Elena Vasilieva; Leonid Margolis; Alexander Shpektor Journal: Am J Med Date: 2019-07-08 Impact factor: 4.965
Authors: A Haarala; M Kähönen; T Lehtimäki; J Aittoniemi; J Jylhävä; N Hutri-Kähönen; L Taittonen; T Laitinen; M Juonala; J Viikari; O T Raitakari; M Hurme Journal: Clin Exp Immunol Date: 2012-02 Impact factor: 4.330
Authors: Moyses Szklo; Jingzhong Ding; Michael Y Tsai; Mary Cushman; Joseph F Polak; João Lima; R Graham Barr; A Richey Sharrett Journal: J Cardiovasc Med (Hagerstown) Date: 2009-10 Impact factor: 2.160
Authors: F Apostolou; I F Gazi; A Kostoula; C C Tellis; A D Tselepis; M Elisaf; E N Liberopoulos Journal: J Lipid Res Date: 2009-06-17 Impact factor: 5.922
Authors: Nadezhda A Wall; Colin D Chue; Nicola C Edwards; Tanya Pankhurst; Lorraine Harper; Richard P Steeds; Sarah Lauder; Jonathan N Townend; Paul Moss; Charles J Ferro Journal: PLoS One Date: 2013-02-25 Impact factor: 3.240